Sellas Life Sciences Group Inc (SLS) Stock Price, Quote & News

Company Profile

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is adm...

Industry: Biotechnology

Sector: Healthcare

Phone: 646 200 5278

Website: www.sellaslifesciences.com

Address:

7 Times Square, Suite 2503, New York, United States

Tinytotter Nov. 15 at 1:45 PM

$SLS I love how the Bears post over and over again how a Biotech has dropped in value, diluted, "fraud" LOL.. apparently they have never invested in a Bio...Its literally what 100% of them do - Fraud part until they get through trials and get approvals. Wake up Bears its about the Science at this stage not anything else. Average time to get a drug to market is 10 years... guess where we are at? So Phase 2 trials rocked and now they say the final read out will trash.. Good lord you cant even make up how dumb these fools sound at this point.

0 · Reply

GpsForTheWin009 Nov. 15 at 1:41 PM

$SLS avxl had the same chart as sls, they ceo also did an offering before the results the price collapsed before the readout and the readout was bad and the price tanked

0 · Reply

KiryuKazama Nov. 15 at 1:34 PM

$SLS the run that's coming here will be biblical.

0 · Reply

Mez2anine Nov. 15 at 1:29 PM

$SLS Calling this ‘beggars can’t be choosy’ is exactly the point: strong leaders avoid putting their company in a beggar position to begin with. Shareholders have every right to question timing and execution. Critique isn’t invalid just because someone can imagine a worse scenario.

0 · Reply

BioCancerStop Nov. 15 at 1:07 PM

$SLS So Sterg has set up a study whereby hypothetically if the GPS patients end up living forever then SLS will never be able to end their trial no less get FDA approval. SLS will never be able to talk about the success of the drug and all of this work over a decade has been fruitless. Sounds to be that Sterg has royally f*ckd up the design. Bad enough that BP will collude with the FDA to tank any drug competition but we have a study that may never end. Does anybody think this is rational. If not then when does SLS force the issue with the FDA. Seems to me like we are basically there given the math. And as for taking months to compute results. That is ridiculous. They have all the data except for like 5 or fewer patients and have had it for months years. I'm not buying that this should take past the end of this year for at the very least topline data to be released and given what has been shared difficult to see how GPS can fail. So why in the world is the price at 1.40?

1 · Reply

Mr_Anderson007 Nov. 15 at 12:57 PM

$SLS Also worth a repeat…yes buying Sellas here is like playing GPS for free considering their other drug trial SLS 009 is easily worth 3x the current price RIGHT NOW.

1 · Reply

Mr_Anderson007 Nov. 15 at 12:48 PM

$SLS Worth the daily repeat…

0 · Reply

Heypentaco Nov. 15 at 11:55 AM

$SLS Gotcha bitches, Gotcha. We are close to not being at where awe have been for 4 years. And I know the final BO number will be the biggest. Next you will pivot to getting me to sell before that. Get the fuck out of my face with that.

0 · Reply

Smikke2 Nov. 15 at 11:31 AM

$SLS just look at all the 13f filings this week and all the calls that have been bought by institutions. We’re close.

0 · Reply

BanannenBernhard Nov. 15 at 11:20 AM

$SLS still waiting for Miami news

0 · Reply

SELLAS Life Sciences Group, Inc. (SLS) Discusses Innovation in AML Treatments With Focus on GPS and SLS009 Programs Transcript

Oct 27, 2025, 8:30 AM EDT - 19 days ago

SELLAS Life Sciences Group Announces Exercise of Existing Warrants Held by a Current Institutional Investor for $31 Million in Gross Proceeds

Aug 19, 2025, 9:18 PM EDT - 3 months ago

Sellas Life Sciences: SLS009's Phase 2 Sets Up A Promising 2026

Aug 7, 2025, 8:30 AM EDT - 3 months ago

SELLAS Life Sciences Announces Independent Data Monitoring Committee Periodic Review and Positive Recommendation to Continue Pivotal Phase 3 REGAL Trial of GPS in AML Without Modification

Jul 7, 2025, 8:45 AM EDT - 4 months ago

SELLAS Life Sciences Appoints Linghua Wang, MD, PhD, to Scientific Advisory Board

Jun 5, 2025, 8:45 AM EDT - 5 months ago

SELLAS Life Sciences Expands Scientific Advisory Board with Addition of Two World-Renowned Hematology and Oncology Experts

Jun 2, 2025, 8:00 AM EDT - 5 months ago

SELLAS Presents Preclinical Efficacy of SLS009 in ASXL1 Mutated Colorectal Cancer at 2025 ASCO Annual Meeting

May 20, 2025, 8:00 AM EDT - 6 months ago

SELLAS Life Sciences to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase

May 15, 2025, 8:45 AM EDT - 6 months ago

SELLAS Life Sciences Announces First Pediatric AML Patient Dosed in the Ongoing Phase 2 Trial of SLS009 r/r AML

May 13, 2025, 4:05 PM EDT - 6 months ago

SELLAS Life Sciences Reports First Quarter 2025 Financial Results and Provides Corporate Update

Apr 28, 2025, 8:45 AM EDT - 7 months ago

SELLAS Unveils Breakthrough Preclinical Data Highlighting Efficacy of SLS009 in TP53 Mutated AML at the 2025 AACR Conference

Apr 23, 2025, 10:23 AM EDT - 7 months ago

SELLAS to Present at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 8, 2025, 8:45 AM EDT - 7 months ago

SELLAS Announces Positive Overall Survival in Cohort 3 from the Ongoing Phase 2 Trial of SLS009 in r/r AML

Mar 31, 2025, 3:03 PM EDT - 8 months ago

Sellas Life Sciences: A Hold For Now With Huge, But Uncertain, Near-Term Catalyst

Mar 20, 2025, 4:05 PM EDT - 8 months ago

SELLAS Life Sciences Reports Full Year 2024 Financial Results and Provides Corporate Update

Feb 20, 2025, 8:45 AM EST - 9 months ago

SELLAS Announces Positive Data from Phase 2a Trial of SLS009 in Combination with Zanubrutinib in DLBCL

Jan 28, 2025, 3:11 PM EST - 10 months ago

SELLAS Life Sciences Group Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 23, 2025, 8:10 AM EST - 10 months ago

SELLAS Life Sciences Announces Positive Outcome of Interim Analysis for its Pivotal Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia

Jan 8, 2025, 8:20 AM EST - 11 months ago

SELLAS Announces Key Business Objectives for 2025

Dec 10, 2024, 8:30 AM EST - 1 year ago

SELLAS Life Sciences Triggers Interim Analysis in Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia

Dec 9, 2024, 8:45 AM EST - 1 year ago

SELLAS Announces Positive Overall Survival and Overall Response Rate Data from the Phase 2 Trial of SLS009 in r/r AML

Nov 27, 2024, 8:45 AM EST - 1 year ago

SELLAS Announces Positive Data from Preclinical Studies Indicating ASXL1 Mutations as Predictor of Response to SLS009 in Solid Cancers

Nov 13, 2024, 4:15 PM EST - 1 year ago

SELLAS Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 13, 2024, 8:00 AM EST - 1 year ago

voxeljet, Dressler Group GmbH, Fraunhofer IPA and the University of Bayreuth Collaborate in Re-Processing of Discarded PA12 Powder for 3D Printing via High-Speed Sintering (HSS)

Nov 5, 2024, 9:55 AM EST - 1 year ago

SELLAS Life Sciences to Present at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition 2024

Oct 15, 2024, 8:45 AM EDT - 1 year ago

SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to Galinpepimut-S (GPS) for the Treatment of Pediatric Acute Myeloid Leukemia

Oct 10, 2024, 4:05 PM EDT - 1 year ago

SELLAS Life Sciences to Participate in Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

Aug 13, 2024, 4:10 PM EDT - 1 year ago

SELLAS Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 6, 2024, 8:45 AM EDT - 1 year ago

SELLAS Receives EMA Orphan Drug Designation for SLS009 for Treatment of Peripheral T-cell Lymphomas

Jul 16, 2024, 9:05 AM EDT - 1 year ago

SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to SLS009 for the Treatment of Pediatric Acute Myeloid Leukemia

Jul 8, 2024, 8:45 AM EDT - 1 year ago

SELLAS Receives European Medicines Agency Orphan Drug Designation for SLS009 for the Treatment of Acute Myeloid Leukemia

Jun 24, 2024, 9:05 AM EDT - 1 year ago

SELLAS Announces U.S. FDA Rare Pediatric Disease Designation Granted to SLS009 for the Treatment of Pediatric Acute Lymphoblastic Leukemia

Jun 17, 2024, 9:05 AM EDT - 1 year ago

SELLAS Life Sciences Announces Positive Recommendation from the Independent Data Monitoring Committee of the Phase 3 REGAL Trial in Acute Myeloid Leukemia

Jun 10, 2024, 8:40 AM EDT - 1 year ago

SELLAS Announces Completion of Enrollment and Initial Positive Data in Phase 2a Trial of SLS009 in r/r AML

May 14, 2024, 4:05 PM EDT - 1 year ago

SELLAS Life Sciences Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 1, 2024, 8:35 AM EDT - 1 year ago

SELLAS Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose Level

Apr 29, 2024, 8:45 AM EDT - 1 year ago

SELLAS Life Sciences Announces Positive Recommendation of Independent Data Monitoring Committee Following Completion of Enrollment in REGAL Phase 3 Study

Apr 19, 2024, 1:49 PM EDT - 1 year ago

Sellas Life Sciences Group: A Lottery Ticket With An Estimated 9x Payout

Mar 28, 2024, 4:05 PM EDT - 1 year ago

SELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate Update

Mar 26, 2024, 7:35 AM EDT - 1 year ago

SELLAS Announces Positive Topline Data from the Phase 2a Study of SLS009 in r/r AML and Provides Steering Committee Update on Phase 3 REGAL Study

Mar 19, 2024, 4:05 PM EDT - 1 year ago

SELLAS Life Sciences Group Announces Closing of $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

Mar 19, 2024, 8:47 AM EDT - 1 year ago

SELLAS Life Sciences to Host Corporate Update Call on March 26, 2024, at 8:15 am ET

Mar 15, 2024, 9:00 AM EDT - 1 year ago

SELLAS Life Sciences Group Announces $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

Mar 8, 2024, 8:00 AM EST - 1 year ago

SELLAS Announces Executive Leadership Reorganization and Prioritization of Commercialization Partnerships

Mar 1, 2024, 8:30 AM EST - 1 year ago

SELLAS Life Sciences Delivers Oral Presentation of SLS009 Phase 1 Data for Acute Myeloid Leukemia Patients at 2024 European School of Haematology (ESH) Conference

Feb 29, 2024, 8:00 AM EST - 1 year ago

SELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference: Updated Date and Time

Feb 6, 2024, 8:30 AM EST - 1 year ago

SELLAS Announces Publication of Preclinical Data on its Highly Selective CDK9 Inhibitor, SLS009, in Oncotarget

Jan 25, 2024, 8:45 AM EST - 1 year ago

SELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference

$SELLAS Life Sciences Receives FDA Fast Track Designation for SLS009 for Treatment of Relapsed/Refractory Acute Myeloid Leukemia and Provides Updated Data for Phase 2a Study of SLS009 in Relapsed/Refractory Acute Myeloid Leukemia Patients$

Jan 9, 2024, 8:30 AM EST - 2 years ago

SELLAS Life Sciences Receives FDA Fast Track Designation for SLS009 for Treatment of Relapsed/Refractory Acute Myeloid Leukemia and Provides Updated Data for Phase 2a Study of SLS009 in Relapsed/Refractory Acute Myeloid Leukemia Patients

Jan 4, 2024, 9:01 AM EST - 2 years ago

SELLAS Life Sciences Announces Pricing of $9.0 Million Public Offering

Tinytotter Nov. 15 at 1:45 PM

0 · Reply

GpsForTheWin009 Nov. 15 at 1:41 PM

$SLS avxl had the same chart as sls, they ceo also did an offering before the results the price collapsed before the readout and the readout was bad and the price tanked

0 · Reply

KiryuKazama Nov. 15 at 1:34 PM

$SLS the run that's coming here will be biblical.

0 · Reply

Mez2anine Nov. 15 at 1:29 PM

0 · Reply

BioCancerStop Nov. 15 at 1:07 PM

1 · Reply

Mr_Anderson007 Nov. 15 at 12:57 PM

$SLS Also worth a repeat…yes buying Sellas here is like playing GPS for free considering their other drug trial SLS 009 is easily worth 3x the current price RIGHT NOW.

1 · Reply

Mr_Anderson007 Nov. 15 at 12:48 PM

$SLS Worth the daily repeat…

0 · Reply

Heypentaco Nov. 15 at 11:55 AM

0 · Reply

Smikke2 Nov. 15 at 11:31 AM

$SLS just look at all the 13f filings this week and all the calls that have been bought by institutions. We’re close.

0 · Reply

BanannenBernhard Nov. 15 at 11:20 AM

$SLS still waiting for Miami news

0 · Reply

Babilon1210 Nov. 15 at 11:10 AM

$SLS The only realistic way for results NOT to be VERY strong is if the control arm is somehow surviving far beyond anything ever seen in this disease. Given historical survival, this is highly unlikely.

0 · Reply

Chasse_patate Nov. 15 at 10:41 AM

$SLS I'll keep my word, but couldn't resist yesterday's prices, bought a little yesterday, 24K now, the rest if it really falls below $1.4.

1 · Reply

Babilon1210 Nov. 15 at 10:39 AM

$SLS Why is this related to SLS?

1 · Reply

Beavis99 Nov. 15 at 9:52 AM

$SLS https://www.nasdaq.com/press-release/genius-group-files-federal-securities-class-action-lawsuit-against-citadel-securities

1 · Reply

Heypentaco Nov. 15 at 9:50 AM

$SLS And....Im going to invest in the company that buys SLS. You got that you scummy, scammy losers?

0 · Reply

Gps_100X_ROI_Potential Nov. 15 at 8:48 AM

$SLS Any day Now. We are now +20 months since Enrollment completed, 126 patients and 105 ‘em completed enrollment 24 + Months ago. - AML CR2 Patients on BAT do not live past 20 months - not even rare outliers. There are Many Recent Trial Publications with AML Patients who Get into Second Remission with NIL Survival Past 20 months. +/-60 Events JUST FROM THE CONTROL ARM - and we have YET TO SEE 80.... WHAT DOES THAT TELL YOU? BAT / Aza+Ven Recently FAILED 3 Phase 3 AML TRIALS, including 2 AML Maintenance Trials - for CR1 and Post ASCT - FAILED. AZA VEN Has Failed REGAL P3 Control Patients too.

1 · Reply

Gps_100X_ROI_Potential Nov. 15 at 8:45 AM

$SLS 8% of SLS was Owned by Institional Funds when the IDMC UNBLINDED THE ACTUAL PHASE 3 MOS and IR DATA ... has to be Up over 50% Now. $SLS We are now +20 months since Enrollment completed 126 patients. 105 completed enrollment 24 + Months ago. - AML CR2 Patients on BAT do not live past 20 months - not even rare outliers. There are Many Recent Trial Publications with AML Patients who Get into Second Remission with NIL Survival Past 20 months. +/-60 Events JUST FROM THE CONTROL ARM - and we have YET TO SEE 80.... WHAT DOES THAT TELL YOU? BAT for the SLS REGAL p3 Control ARM / Aza+Ven Recently FAILED 3 Phase 3 AML TRIALS -- Hello -- including 2 AML Maintenance Trials - for CR1 and Post ASCT - FAILED. AZA VEN Has Failed REGAL P3 Control Patients too.

0 · Reply

Marcus737 Nov. 15 at 6:36 AM

$SLS Confidence:) Call buyers getting wrecked. Short fee below 19% now.

1 · Reply

GFstocktwits Nov. 15 at 5:47 AM

$SLS Great price level to buy at

0 · Reply

Bunster Nov. 15 at 5:44 AM

$SLS newbie did u see they had 4.9pct on june 30... prime

1 · Reply

vlucky16 Nov. 15 at 4:53 AM

$SLS Unfortunately in the world of US FDA is a little thing known as SOP. Slows down and kills a lot of good ideas that would make the govt work better. Don't use your brains and approve of a drug that has proven safety, and is much better than the current SOC, just follow the SOP to the end.

0 · Reply

RealImbackbears Nov. 15 at 4:42 AM

$SLS stfu you work for them Also they are borrowing out shares to short . That's how they make money, they could care less about this company. They are ready to bankrupt everyone but themselves and the CEO will just keep giving cheap warrants to Anson Btw you have no common sense LIB

1 · Reply

Market Cap	182.62M
Revenue (ttm)	0.00
Net Income (ttm)	-30.88M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	3,257,400
Avg Vol	3,736,754
Day's Range	N/A - N/A
Shares Out	125.08M
Stochastic %K	8%
Beta	2.64
Analysts	Strong Sell
Price Target	$6.83